Table 2.

Chronic kidney disease mineral and bone disorder medication use among dialysis patients enrolled in Medicare Part D, 2007–2010

	All				Without LIS				With LIS
Medication	2007	2008	2009	2010	2007	2008	2009	2010	2007	2008	2009	2010
No. of patients	198,349	209,972	220,051	231,320	55,134	60,360	64,335	67,446	143,215	149,612	155,716	163,874
Phosphate binder
Calcium acetate	40.6	39.7	39.2	38.7	38.5	37.3	37.0	36.9	41.3	40.6	40.1	39.4
Lanthanum carbonate	13.0	12.0	11.3	9.5	10.1	8.5	7.3	6.0	14.1	13.4	12.9	10.9
Sevelamer carbonate	0.0	5.3	23.2	43.0	0.0	4.1	20.1	33.7	0.0	5.7	24.5	46.7
Sevelamer hydrochloride	52.2	51.3	40.3	19.9	42.4	41.0	28.8	11.4	55.9	55.4	44.9	23.3
Sevelamer	52.2	53.2	53.5	54.2	42.4	42.7	41.9	41.2	55.9	57.4	58.2	59.4
Any phosphate binder	83.0	83.2	83.2	82.6	74.4	73.7	72.5	71.4	86.2	87.0	87.5	87.1
Oral vitamin D analogue
Calcitriol	5.5	5.8	6.0	6.3	5.6	6.2	6.2	6.5	5.4	5.7	5.9	6.3
Doxercalciferol	2.4	2.3	2.2	2.2	2.2	2.0	1.9	1.8	2.4	2.4	2.4	2.3
Paricalcitol	1.2	1.4	1.8	2.0	1.2	1.5	1.8	2.1	1.2	1.4	1.8	2.0
Any oral vitamin D analogue	8.5	9.1	9.5	9.9	8.5	9.2	9.3	9.8	8.6	9.0	9.5	10.0
IV Vitamin D analogue
Calcitriol	2.4	1.7	1.6	1.8	1.5	1.1	1.0	1.1	2.7	1.9	1.8	2.0
Doxercalciferol	27.4	22.4	20.9	35.4	21.7	17.7	16.3	26.6	29.6	24.2	22.7	39.0
Paricalcitol	59.4	62.5	62.4	65.0	47.9	50.0	49.6	51.2	63.7	67.5	67.5	70.5
Any IV vitamin analogue	79.3	79.1	77.5	77.5	63.6	63.2	61.3	60.4	85.2	85.4	84.1	84.4
Calcimimetic
Cinacalcet	31.8	33.3	31.9	31.0	21.2	22.3	21.0	20.8	35.8	37.7	36.3	35.1

Note: Values are given as percentages.

LIS, low-income subsidy; IV, intravenous.